Glenmark Pharmaceuticals' US subsidiary will pay $29.6 million to resolve antitrust and consumer protection claims over alleged generic drug price-fixing in the United States.
The case was related to allegations of generic drug price-fixing
May 23, 2026
05:11 pm
What's the storyGlenmark Pharmaceuticals has announced that its US subsidiary will pay $29.6 million (approximately ₹284 crore) to settle antitrust and consumer protection litigation.
The case was related to allegations of generic drug price-fixing in the US.
Attorneys at Hagens Berman Announce $474M Win in Amitiza Jury Trial Against Takeda
Takeda faces $885m hit after landmark pay-for-delay lawsuit verdict - Pharmaceutical Technology
India's Adani to pay $275 mn settlement to US over alleged Iran sanctions violations
India’s Adani to pay $352m settlement to US over alleged Iran sanctions violations
Takeda found liable over antitrust plot to delay generic constipation drug
Takeda slapped with $885M verdict in pay-for-delay antitrust case
Goldman Sachs to pay US$500 million to settle shareholder lawsuit over 1MDB scandal
Authorities allege Pernod Richard withheld Scotch composition, age in effort to pay lower tariffs under $314 mln refund case
Adani Group, top officials settle all legal cases in US
Jury Hits Takeda With $885 Million Antitrust Verdict - Takeda Pharmaceutical Co (NYSE:TAK)
The deal would give GSK the rights to develop the drug for HRD-9821 and 11 preclinical programmes owned by Jiangsu Hengrui…
WASHINGTON — Indian billionaire Gautam Adani and his nephew Sagar Adani have agreed to pay a combined $18 million in penalties to…
Attorneys at Hagens Berman Announce $474M Win in Amitiza Jury Trial Against Takeda
The company is the latest pharma firm to have either reduced spending in the UK or diverted it to the US.
Takeda confirmed it would appeal the outcome, stating that the case “lacks merit”.
A grand jury indicted a California firm for allegedly running an Adderall distribution scheme, health care fraud and attempting…
